NCP 112
Alternative Names: NCP-112Latest Information Update: 22 Feb 2024
At a glance
- Originator DongKoo Bio&Pharma
- Class Peptides; Skin disorder therapies
- Mechanism of Action FPR2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis
Most Recent Events
- 22 Feb 2024 Huons plans a phase I trial for (In volunteers, In adults) in June 2024 (NCT06263998)
- 16 Dec 2021 Preclinical trials in Atopic dermatitis in South Korea (unspecified route) as of December 2021 (DongKoo Bio&Pharma pipeline; December 2021)
- 20 Nov 2021 NovaCell Technology completes a phase I trial in Atopic dermatitis (In volunteers) in South Korea (Topical) (NCT05638165)